HRP20030762A2 - A stable pharmaceutical formulation comprising torsemide modofication ii - Google Patents

A stable pharmaceutical formulation comprising torsemide modofication ii

Info

Publication number
HRP20030762A2
HRP20030762A2 HR20030762A HRP20030762A HRP20030762A2 HR P20030762 A2 HRP20030762 A2 HR P20030762A2 HR 20030762 A HR20030762 A HR 20030762A HR P20030762 A HRP20030762 A HR P20030762A HR P20030762 A2 HRP20030762 A2 HR P20030762A2
Authority
HR
Croatia
Prior art keywords
torsemide
stable pharmaceutical
modofication
high purity
pharmaceutical formulation
Prior art date
Application number
HR20030762A
Other languages
English (en)
Inventor
Leibovici Minutza
Kopel Mira
Kordova Marco
Tenengauzer Ruth
Aronhime Judith
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030762(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20030762A2 publication Critical patent/HRP20030762A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20030762A 2000-02-17 2001-02-21 A stable pharmaceutical formulation comprising torsemide modofication ii HRP20030762A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18328800P 2000-02-17 2000-02-17
US09/789,424 US6482417B2 (en) 2000-02-17 2001-02-21 Stable pharmaceutical formulation comprising torsemide modification II
PCT/US2001/005577 WO2002067935A1 (en) 2000-02-17 2001-02-21 A stable pharmaceutical formulation comprising torsemide modification ii

Publications (1)

Publication Number Publication Date
HRP20030762A2 true HRP20030762A2 (en) 2005-08-31

Family

ID=27359046

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030762A HRP20030762A2 (en) 2000-02-17 2001-02-21 A stable pharmaceutical formulation comprising torsemide modofication ii

Country Status (20)

Country Link
US (1) US6482417B2 (enExample)
EP (1) EP1292303B1 (enExample)
JP (1) JP2004522780A (enExample)
CN (1) CN1505512A (enExample)
AT (1) ATE266404T1 (enExample)
CA (1) CA2410802A1 (enExample)
DE (2) DE1292303T1 (enExample)
DK (1) DK1292303T3 (enExample)
ES (1) ES2193007T3 (enExample)
HR (1) HRP20030762A2 (enExample)
HU (1) HUP0600143A2 (enExample)
IL (1) IL157539A0 (enExample)
IS (1) IS6919A (enExample)
MX (1) MXPA03007908A (enExample)
NO (1) NO20033699L (enExample)
PT (1) PT1292303E (enExample)
SI (1) SI1292303T1 (enExample)
SK (1) SK11632003A3 (enExample)
TR (1) TR200401462T4 (enExample)
WO (1) WO2002067935A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
WO2005044187A2 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
GR1010905B (el) * 2024-04-15 2025-03-10 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Δισκιο που περιεχει τορασεμιδη

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
CA2213700C (en) * 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
HRP20020120A2 (en) * 1999-08-11 2003-10-31 Teva Pharma Torsemide polymorphs

Also Published As

Publication number Publication date
JP2004522780A (ja) 2004-07-29
DK1292303T3 (da) 2004-09-06
EP1292303A4 (en) 2003-07-09
IS6919A (is) 2003-08-20
DE60103276T2 (de) 2005-06-23
SK11632003A3 (sk) 2004-04-06
SI1292303T1 (en) 2004-10-31
MXPA03007908A (es) 2004-12-06
TR200401462T4 (tr) 2004-08-23
EP1292303A1 (en) 2003-03-19
CA2410802A1 (en) 2002-09-06
HUP0600143A2 (en) 2006-10-28
ES2193007T3 (es) 2004-11-01
IL157539A0 (en) 2004-03-28
US6482417B2 (en) 2002-11-19
US20020035135A1 (en) 2002-03-21
WO2002067935A1 (en) 2002-09-06
ES2193007T1 (es) 2003-11-01
DE60103276D1 (de) 2004-06-17
DE1292303T1 (de) 2003-09-18
NO20033699L (no) 2003-10-10
EP1292303B1 (en) 2004-05-12
CN1505512A (zh) 2004-06-16
NO20033699D0 (no) 2003-08-20
ATE266404T1 (de) 2004-05-15
PT1292303E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
UA63993C2 (uk) Фармацевтична лікарська форма, що швидко тане в роті (варіанти) та спосіб формування гранул
GEP20053473B (en) High Potency Dihydroergotamine Compositions
IL153297A0 (en) Compounds and compositions for delivering active agents
WO2002017918A3 (en) Sustained release formulations for growth hormone secretagogues
BG106003A (en) New n-cyanomethylamides and compositions as protease inhibitors
TW200510375A (en) New compounds
PT1412384E (pt) Formulação estável de glp-1 modificado
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
HUP0301349A2 (hu) IL-11-tartalmú készítmények
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
EA200501901A1 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путём
MY127350A (en) Flash-melt oral dose formulations
IL150528A0 (en) Ibuprofen containing active agent preparation
BG106155A (en) Novel derivatives and analogues of galanthamin
DK1007006T3 (da) Formulering af cefadroxilmonohydrattablet
AP2003002763A0 (en) Controlled release formulations for oral administration
IL98881A0 (en) Esters of heterocyclic compounds,their preparation and pharmaceutical compositions containing them
IL157539A0 (en) A stable pharmaceutical formulation comprising torsemide modification ii
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070125

Year of fee payment: 7